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and vice versa. If not treated, the hyperglycemia may go 
onto fulminant diabetes mellitus and its effects on end 
organ damage like kidneys, eyes, heart, and brain can be 
fatal in type II diabetes mellitus.[4,5] The prevalence of 
diabetes mellitus is attributed to ethnicity while living 
in the same environment.[6] However, western life style 
accelerates its prevalence. Diabetes mellitus can be better 
managed with control on diet, though pharmacotherapy 
is one the best option once the disease goes out of 
control.[7] However, poly-pharmacy carries risks of 
drug interactions and adverse drug reactions.[8] Hence, 
we analyzed retrospectively the treatment charts of the 
INTRODUCTION 
Hyperglycemia may be due to insufficient insulin or poor 
response to insulin. Hyperglycemia may also be present 
with altered metabolism of lipids, carbohydrates, and 
proteins with increased risk of cardiovascular diseases.[1]
Sedentary life style is a major cause of obesity that is a 
factor for diabetes mellitus in middle-age population.  [2] 
Disorder of lipid metabolism and hypertension may 
be seen in the diabetic patients.[3] It is an admitted fact 
that the larger the waist belt, the shorter will be the life 
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ABSTRACT
A total of 856 diabetic patients were evaluated for pharmacotherapy-based problems like for possible drug 
interactions, adverse drug reactions, and other mismatches, if any. Poor correlation between the advised insulin 
therapy and patients’ fasting blood glucose levels (12%, n=103) was observed. To most of the patients (41.66%, 
n= 357), insulin therapy was advised in combination with glucocorticoides, thiazides diuretics, and propranolol. 
Prescribing beta blocker (propranolol) with insulin is contraindicated. The higher incidence of diabetic foot 
patients was in the mean age of 57±3.4 years that was controlled with combination therapy of insulin and oral 
antidiabetics (63.0%, n=516). 11.1% of the treated patients could not take the prescribed therapy due to poor 
acceptance of insulin therapy due to its syringe needle prick. 41.66% risks of potential drug interactions, 7.93% 
adverse drug reactions, and 6.6% mismatches were recorded, as per the international approved algorithm, for 
managing a diabetes mellitus that reflects poor health care system. All these events necessitate for coordinating 
with other health professionals to make the therapy safer in the better interest of the patients. It is concluded 
that in practice prescribing pattern carries more risks for patients. It is imperative to improve the practice of 
pharmacotherapeutics rather than to practice in routine.   
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patients for possible pharmacotherapy therapy-based 
problems.
MATERIALS AND METHODS
Collection of data
Data were recorded, on the prescribed history form, 
using “purposive sampling techniques” over a period of 3 
months in the respective teaching hospitals of the province. 
We could interview a total of 856 patients through 
skilled internees of Pharm-D Program in the prescribed 
period. Authenticity of the data was guaranteed as it was 
recorded in the prescribed history forms, concurrently, 
by the internees. The data were analyzed, retrospectively, 
for review of patients’ medication charts for possible 
pharmacotherapy problems.[9] Main drug therapy and 
supportive drug therapy with potential drug interactions 
are listed in Table 1.
Diabetes mellitus is some time associated with other 
concurrent ailments like diabetic foot (the major cause 
of hospitalization in diabetics); therefore, relatively more 
drugs were prescribed for the total management of type 
II diabetic patients. Hence, we considered the algorithm 
described by Cantrill and Wood,[7] and Barar[10,11] for the 
management of diabetes as standard protocols.
Diagnosis and treatment
Respective ward physicians diagnosed the cases. All relative 
biochemical tests were performed as per the advice of 
respective ward physicians. 
Definitions
Main drug therapy: Drugs prescribed to control hyperglycemia 
that include either oral hypoglycemics or insulin therapy 
or combination of both as specified elsewhere in the text 
of this paper.
Supportive drug therapy: Drugs prescribed other than 
mentioned in the main drug therapy that mostly include 
antibiotic therapy, antiemetics, diuretics corticosteroids, and 
other drugs for concurrent ailments either to increase the 
potency or to decrease the side effects, if any. 
Adverse drug reaction: An adverse drug reaction was defined 
as an unwanted effect associated with drug therapy, 
including main and supportive drug therapies that could 
lead to either discontinuation or altering the course of 
therapy.
Potential risks of  drug interactions: Combination of two or 
more than two drugs used in the therapy with reported 
harmful effects on the health or quality of life of the 
recipients that is/are reported in the medical literature 
that necessitates for either change in the dose regimen or 
to search for suitable therapeutic alternatives.
Statistical analysis
Microsoft XL sheet was used to calculate the percentage, 
mean, and standard deviation for variables mentioned 
elsewhere in the text. 
RESULTS AND DISCUSSION
As mentioned in Table 1, total 856 diabetic patients were 
admitted in the hospitals. Therapy was advised for control 
of their major illness i.e. hyperglycemia with concurrent 
cases like diabetic foot. It is evident that to 69.84% cases 
(n= 600, type I and type II inclusive), insulin therapy was 
advised. In certain cases, combination therapy of insulin and 
oral hypoglycemics (60.3 %, n= 516) were tried to control 
hyperglycemia. According to Table 1, among the prescribed 
oral hypoglycemics, metformen was most frequently 
(39.68 %, n= 360) prescribed. The oral hypoglycemics 
were of the order: metformen (39.68%) > glibenclamide 
(12.69%) > glimeperide (9.52 %) > pregabaline (7.93%) 
> gilipizide (4.76%) = gliclazide (4.76%) > tolbutamide 
(1.58%). Interestingly, the hyperglycemia was controlled 
with insulin therapy. But there was no correlation of 
blood glucose levels with insulin therapy that lead to 
hypoglycemia that was observed in 12% of the reported 
cases (data not shown). The main reason of negligence, in 
this regard, was due to the fact that the laboratory reports 
were received at 11:00 am and the patients had to receive 
their advised insulin therapy in the morning between 8:00 
and 9:00 am that reflects poor correlation of the therapy 
with patients’ biochemical tests. In Table 1, as per reported 
medical literature, potential drug interactions are listed that 
required interventions but were not intervened. To most 
of the patients (41.66%, n= 357), insulin therapy was 
advised in combination with glucocorticoides, thiazides 
diuretics, and propranolol. Insulin and glucocorticoids 
combination increases hyperglycemia and decreases 
affinity of tissue receptors response to insulin.[11,12] It is 
noteworthy that thiazide diuretics decreases the sensitivity 
of insulin to its receptors and of course its secretion as 
well.[13,14] Metformen was prescribed to a renally impaired 
patient (a contrindications of metformen).[15] Combination 
of beta blockers (BBs) can be dangerous not only in a 
sense that BBs decrease the secretions of insulin from J Young Pharm Vol 2 / No 3  313
the islets of Langerhans but also mask the symptoms of 
reflex tachycardia that is regarded as a vital force (to me 
personally) in combating hypoglycemia and can be fatal.  [16] 
Combination of aspirin and heparin combination have 
reported with GIT bleeding[17] that was not intervened as 
suggested in Table 1. The higher incidence of diabetic foot 
patients was in the mean age of 57±3.4 years (data not 
shown). Hence, more care should be exercised in patients 
with mean age 57±3.4 years and insulin regimen should 
be incorporated for the management of hyperglycemia to   
help prevent them from complication of diabetic 
foot rather than to wait and let the patient goes on to 
complications.[19,20] In this regard, a comprehensive 
awareness program is necessary to change the mind set of 
diabetic patients about the insulin therapy and give them 
awareness about diabetic foot as a complication. Having 
done this accordingly, as stated earlier, the patients will 
keep on taking advised insulin therapy and they will not go 
onto diabetic foot, the major cause of hospitalization.[19,20] 
All the events related to pharmacotherapy problems are 
summarized in Table 2 in light of the algorithm described 
by Yarborough PC.[9] Out of the total patients, 11.11% 
could not take the prescribed drugs due to pharmaceutical-
based problems like poor acceptance to insulin syringe 
prick. The reported ADRs were diarrhea (7.69%), burning 
micturation, and weakness (2.0%). 41.66% of the cases 
carried potential risks of drug interactions and the most 
frequently encountered drug interactions are mentioned 
in Table 1. Self-explanatory mismatches are summarized 
in Table 2 that are 20.0% in the main drug therapy and 
41.26% in the supportive drug therapy that lead to a high 
antibiotic number per patients (2.4/patient). To 6.6% of 
the cases, no relevant drug therapy was prescribed for 
indications such as hypertension, hepatitis, diarrhea, fatigue, 
and burning feet syndrome and stress. This reflects poor 
patient’s health care system that requires improvements 
Table 1: Main and supportive pharmacotherapy with potential drug interactions
Main regular therapy advised for the management 
diabetes mellitus
Potential drug interactions among the prescribed therapy and drug disease*  
interaction
Characteristics n % of total† Combination used Remarks and interventions
All patient 856 100 INS + glucocorticoids Increases blood sugar by stimulation of gluconeogenesis, mobilization 
of fats, decreases affinity of tissue receptors for insulin.[11] Take actions 
as necessary.
Insulin (INS) therapy‡ 600 69.84 INS + thiazides Thiazides cause hypokalemia that decreases insulin secretion and 
receptor sensitivity insulin.[12,13] Watch for diabetic control when 
thiazides are given together with any antidiabetic.
Oral hypoglycemics§ - -
Metformen
 (MTF)
640 39.68
Glipazide 41 4.76 MTF + renal insufficiency* Drug disease interaction as it increases the lactic acidosis that requires 
hemodialysis.[14]
Glibenclamide (GBD) 109 12.69
Glimiperide (GLM) 81 9.52 INS + propranolol Inhibition of insulin secretion and inhibition of the symptoms of 
hypoglycemia. Look for Cardio selective Beta blockers.[15]
Pregabaline (PRG) 68 7.93
Gliclazide (GLD) 109 4.76 Aspirin + heparin Avoid the combination as it may increase bleeding. Look for non 
salicyllates or give oral anticoagulant.[16]
Tolbutamide (TMD) 14 1.58 ACEIs + aspirin Renal failure if combination used for months as supportive therapy 
Shift to acetaminophen instead aspirin.[17,18]
*Drug disease interaction, †Cumulative number may be more than 100% as more than one class of drugs was prescribed to same patient. Abbreviations are used in parenthesis, 
‡Including type I and type II diabetic patients, §Oral drugs prescribed to type II diabetic patients.
Table 2: Data extracted from the history forms to show the % incidence of pharmacotherapy based problems*
Pharmaceutical  
based problems
Risks to patients Mismatches Efficacy
Main drug therapy Supportive drug therapy
Patients not 
receiving 
prescribed drugs
Routine 
monitoring 
missing like 
correlation with 
lab findings
Adverse Drug 
Reactions
Drug 
Interactions
No indications 
for current drug 
prescribed
Indication for 
drug exists but 
not prescribed
No indications 
for current drug 
prescribed
Indication 
for drug 
exists but not 
prescribed
Wrong drug or 
regimen prescribed 
/ more efficacious 
choice available
11.11% 12% 7.93% 41.66% 20.6% 0% 41.26% 6.6% 4.7%
*%Cumulative incidence may be more than 100 as more than one type of problems were observed in same patient.
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in light of the practice of rational therapeutics. Hence, it 
is imperative to improve the practices of therapeutics by 
providing our health professionals a patient’s based learning 
rather than to practice in routine.[21] Poly-pharmacy leads 
to many ADRs that can be anticipated by interdisciplinary 
integration of disciplines such as medicine, pharmacy, and 
other health professions for the promotion of practice 
of rational therapeutics. A “medication review team”[22] 
including pharmacists and physicians may be constituted 
throughout the country to give concise recommendations 
and corrective measures for proper utilization of drugs.
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